New Products In Brief
Unisom extension targets nighttime pain: Sanofi-Aventis introduces the first dual-ingredient stock-keeping unit in the Unisom sleep-aid line, pairing diphenhydramine 50 mg with acetaminophen 325 mg in Unisom PM Pain SleepCaps. The product sells at $8.99 for 30 caplets. Unisom PM Pain's indication says it helps "relieve occasional sleeplessness when accompanied by a headache or other minor aches and pains," according to its website. Johnson & Johnson/McNeil is seeking FDA approval of a more explicit sleep-aid/pain relief indication for its similar Tylenol PM (diphenhydramine 25 mg/acetaminophen 500 mg) (1"The Tan Sheet" Aug. 23, 2010)
More from Archive
- • By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
- • By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
- • By
It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.
- • By
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
- • By
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.




